Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
Editor-in-Chief
HCV Advocate
HBV Advocate

Thursday, September 13, 2012

Limbrel (Flavocoxid) Linked to Acute Liver Injury

Flavocoxid may cause clinically significant liver injury in some patients, according to study results published in the Annals of Internal Medicine. Flavocoxid is a medical food, marketed under the name of Limbrel, for the treatment of osteoarthritis.

Researchers linked 4 cases of liver injury to flavocoxid, based on the records of 877 patients followed by the national Drug-Induced Liver Injury Network. All four people developed signs of liver injury within one to 3 months of starting flavocoxid. The connection to flavocoxid use was considered very likely in 3 of the 4 cases and possible in one of the cases. The good news is that once the product is stopped, liver problems resolve within weeks.

Read more...

No comments:

Post a Comment